Delivery Order SPE2DB20D3103-SPE2DB26FL5G1
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $3,103.31. This firm fixed-price delivery order, which is expected to be completed by November 4, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,540.46 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count package). This non-set-aside, competitively awarded contract utilizes a firm fixed price structure with performance completion targeted for November 10, 2025. The award was issued on November 7, 2025, and AmerisourceBergen will perform the delivery from its corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $4,606.47. This delivery order represents a firm fixed-price, non-set-aside contract to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90 count) under a firm fixed-price contract valued at $8,854.17. The order was competitively awarded without set-aside designation and is scheduled for completion by October 21, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order represents a transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $6,194.63. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be performed in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $5,724.78. The award was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,640.77 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on July 11, 2025, with an ultimate completion date of July 14, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for 90 tablets of Gemtesa 75 mg with a ceiling value of $7,551.80 under a Firm Fixed Price contract structure. This is a non-set-aside competitive award with an ultimate completion date of October 30, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's ongoing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Gemtesa 75 mg tablets (90-count package) valued at $9,243.98 under a firm fixed-price contract. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was made on a competitive basis with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $14,891.75 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90 count) on November 6, 2025, with completion scheduled for November 7, 2025. This firm fixed-price contract is a non-set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a total value of $999,999,999.00 and extends through December 2026. The pharmaceutical...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB26FL5G1Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract type with a ceiling value of $8,085.80. This non-set-aside award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of November 7, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a prime vendor agreement valued at $999,999,999.00 and extending through December 2026, which supports comprehensive pharmaceutical supply needs across military healthcare systems worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly for Defense Health Agency and military healthcare operations. The company maintains an extensive portfolio of federal contract awards with DLA covering a broad spectrum of pharmaceutical products and medical supplies across multiple therapeutic domains. As a competitively awarded prime vendor, AmerisourceBergen has demonstrated capability to fulfill federal medical supply requirements and serves as one of multiple contractors under DLA's Pharmaceutical Prime Vendor Global Program, which operates across separate regional assignments to support U.S. military and veteran healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 11/6/25 |